Sepal Pharma

Sepal Pharma is a French biotechnology company and a spin-off from the Institut Curie, CNRS, and Inserm, specializing in the development of innovative cancer immunotherapies. The company's core focus is the modulation of the Aryl Hydrocarbon Receptor (AhR), a key transcription factor that tumors exploit to create an immunosuppressive microenvironment. By utilizing its proprietary platform to design potent and selective small molecule AhR antagonists, Sepal Pharma aims to reactivate the anti-tumor immune response and overcome resistance to existing treatments. Currently in the pre-clinical stage, the company is advancing its lead candidates toward clinical trials for the treatment of various solid tumors. The founding team combines expertise in medicinal chemistry and immunology to address high unmet medical needs in oncology.